What is the weight‑based dosing of tenecteplase for an adult with acute myocardial infarction?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 9, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Tenecteplase Dosing for Acute Myocardial Infarction

Tenecteplase is administered as a single intravenous weight-based bolus for acute myocardial infarction, with doses ranging from 30 mg to 50 mg based on body weight. 1

Weight-Based Dosing Algorithm

The 2025 ACC/AHA/ACEP/NAEMSP/SCAI guidelines provide the following weight-tiered dosing schedule 1, 2:

  • <60 kg: 30 mg IV bolus
  • 60-69 kg: 35 mg IV bolus
  • 70-79 kg: 40 mg IV bolus
  • 80-89 kg: 45 mg IV bolus
  • ≥90 kg: 50 mg IV bolus

Administration: Given as a single intravenous bolus over 5-10 seconds 3

Key Clinical Context

When to Use Tenecteplase

Tenecteplase is indicated when:

  • Primary PCI cannot be achieved within 2 hours from first medical contact 1
  • Symptom onset is within 12 hours 1
  • Patient has ST-segment elevation myocardial infarction
  • No absolute contraindications exist

Important advantage: Tenecteplase demonstrated equivalent 30-day mortality to alteplase but with reduced noncerebral bleeding complications 1. The single bolus administration is operationally simpler than the 90-minute alteplase infusion.

Pharmacokinetics Supporting This Dosing

The FDA label confirms that tenecteplase exhibits linear pharmacokinetics across the 30-50 mg dose range, with plasma clearance of 99-119 mL/min 3. Body weight explains 19% of variability in plasma clearance, which is why weight-adjusted dosing optimizes therapeutic outcomes 3, 4, 5. The terminal half-life is 90-130 minutes, approximately 4-fold longer than alteplase, enabling single bolus administration 3.

Critical Contraindications to Screen

Absolute contraindications 1, 2:

  • Any prior intracranial hemorrhage
  • Ischemic stroke within 3 months (except acute ischemic stroke within 4.5 hours)
  • Known intracranial neoplasm or vascular malformation
  • Active bleeding or bleeding diathesis
  • Severe uncontrolled hypertension (SBP >180 or DBP >110 mm Hg unresponsive to therapy)
  • Significant closed-head/facial trauma within 3 months
  • Intracranial/intraspinal surgery within 2 months
  • Suspected aortic dissection

Post-Administration Management

Immediately after tenecteplase administration 1:

  • Transfer to PCI-capable center is mandatory
  • Early angiography between 2-24 hours with intent to perform PCI is recommended (Class I, Level B-R)
  • If suspected failed reperfusion occurs, immediate rescue PCI is indicated

Common Pitfalls to Avoid

  1. Do not use tenecteplase in patients with only ST-segment depression (unless true posterior MI suspected) due to increased risk of hemorrhagic stroke 1

  2. Weight estimation errors: Use actual body weight when available. The dose tiers are designed to account for the relationship between weight and drug clearance 3, 4

  3. Timing beyond 12 hours: While benefit is not established beyond 12 hours, consider administration in symptomatic patients with large area at risk or hemodynamic instability if PCI unavailable 1

  4. Concomitant antiplatelet/anticoagulation: Administer aspirin 150-325 mg and weight-adjusted heparin (4000-5000 unit bolus followed by infusion targeting aPTT 50-75 seconds) 3

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.